REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.16−0.02 (-0.28%)
Close on Nov 20, 2026Market cap $472.65MP/E –Yield –
Regenxbio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Regenxbio's free cash flow for the twelve months ending Jun 30, 2026 was -$249.67M. For fiscal 2025 it was -$126.38M. The highest annual figure on record is $134.70M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$126.38M | – |
| FY2024 | Dec 31, 2024 | -$175.56M | – |
| FY2023 | Dec 31, 2023 | -$228.37M | – |
| FY2022 | Dec 31, 2022 | -$238.21M | -276.8% |
| FY2021 | Dec 31, 2021 | $134.70M | – |
| FY2020 | Dec 31, 2020 | -$80.93M | – |
| FY2019 | Dec 31, 2019 | -$119.43M | -230.7% |
| FY2018 | Dec 31, 2018 | $91.37M | – |
| FY2017 | Dec 31, 2017 | -$65.15M | – |
| FY2016 | Dec 31, 2016 | -$56.71M | – |
| FY2015 | Dec 31, 2015 | -$23.04M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$63.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$77.42M | -337.5% |
| Q4 FY2025 | Dec 31, 2025 | -$52.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$49.73M | – |
| Q1 FY2025 | Mar 31, 2025 | $32.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$56.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.85M | – |
| Q2 FY2023 | Jun 30, 2023 | -$49.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$85.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$44.84M | -113.7% |
| Q3 FY2022 | Sep 30, 2022 | -$55.51M | – |
| Q2 FY2022 | Jun 30, 2022 | -$70.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.88M | – |
| Q4 FY2021 | Dec 31, 2021 | $326.88M | +1129.9% |
| Q3 FY2021 | Sep 30, 2021 | -$61.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$75.07M | – |
| Q4 FY2020 | Dec 31, 2020 | $26.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$42.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.54M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.83M | – |
| Q2 FY2019 | Jun 30, 2019 | -$29.30M | -143.4% |
| Q1 FY2019 | Mar 31, 2019 | -$31.75M | -156.9% |
| Q4 FY2018 | Dec 31, 2018 | -$9.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.93M | – |
| Q2 FY2018 | Jun 30, 2018 | $67.54M | – |
| Q1 FY2018 | Mar 31, 2018 | $55.79M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.93M | – |
| Q3 FY2017 | Sep 30, 2017 | -$17.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.23M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.41M | – |
| Q4 FY2016 | Dec 31, 2016 | -$24.86M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.04M | – |
See a number that looks wrong?